secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001104659-21-097239
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q2 sales $11.4B (+22% YoY); raises full-year revenue guidance to $46.4B-$47.4B
--------------------------------------------------------------------------------

- GAAP EPS $0.48; non-GAAP EPS $1.31, up 28% YoY on strong demand recovery.
- KEYTRUDA sales $4.2B (+23%); GARDASIL $1.2B (+88%) driven by pandemic recovery.
- Completed Organon spinoff on June 2; received ~$9B cash distribution.
- Full-year non-GAAP EPS guidance raised to $5.47-$5.57, including ~2% FX benefit.
- FDA approvals for VAXNEUVANCE, KEYTRUDA in TNBC and endometrial carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465921097239/0001104659-21-097239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465921097239/tm2123400d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-097239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer